Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
humans (16) 16
female (15) 15
hematology (15) 15
middle aged (15) 15
oncology (15) 15
male (14) 14
aged (13) 13
cancer (13) 13
adult (12) 12
life sciences (12) 12
lymphomas (10) 10
rituximab (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
chemotherapy (9) 9
aged, 80 and over (8) 8
lymphoma (8) 8
treatment outcome (7) 7
care and treatment (6) 6
retrospective studies (6) 6
[sdv.can]life sciences [q-bio]/cancer (5) 5
adolescent (5) 5
analysis (5) 5
disease-free survival (5) 5
management (5) 5
relapse (5) 5
therapy (5) 5
transplantation (5) 5
[sdv]life sciences [q-bio] (4) 4
antineoplastic agents - therapeutic use (4) 4
combined modality therapy (4) 4
follow-up (4) 4
patients (4) 4
response criteria (4) 4
survival (4) 4
survival analysis (4) 4
trial (4) 4
young adult (4) 4
[ sdv.can ] life sciences [q-bio]/cancer (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
b-cell lymphoma (3) 3
central nervous system (3) 3
drug administration schedule (3) 3
follow-up studies (3) 3
hematology, oncology and palliative medicine (3) 3
hemic and lymphatic diseases (3) 3
medical research (3) 3
medicine, experimental (3) 3
methotrexate (3) 3
primary cns lymphoma (3) 3
prognosis (3) 3
radiotherapy (3) 3
recurrence (3) 3
remission induction (3) 3
safety (3) 3
stem cell transplantation (3) 3
stem cells (3) 3
survival rate (3) 3
1st-line treatment (2) 2
[ sdv ] life sciences [q-bio] (2) 2
angiogenesis (2) 2
antibodies, monoclonal, murine-derived - administration & dosage (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
article (2) 2
autografts (2) 2
bone marrow (2) 2
combination (2) 2
consolidation (2) 2
cyclophosphamide (2) 2
cytarabine (2) 2
cytarabine - administration & dosage (2) 2
dasatinib (2) 2
double-blind (2) 2
drug resistance, neoplasm (2) 2
efficacy (2) 2
elderly-patients (2) 2
epistaxis (2) 2
era (2) 2
experience (2) 2
follicular lymphoma (2) 2
france (2) 2
geriatrics (2) 2
hema10 (2) 2
hodgkin disease - mortality (2) 2
hodgkin lymphoma (2) 2
hodgkin's disease (2) 2
human health and pathology (2) 2
ibrutinib (2) 2
immune system diseases (2) 2
immunotherapy (2) 2
interferon-alpha (2) 2
international prognostic index (2) 2
kaplan-meier estimate (2) 2
lymphocytic leukemia (2) 2
lymphoma - drug therapy (2) 2
lymphoma, follicular - drug therapy (2) 2
lymphoma, follicular - mortality (2) 2
lymphoma, large b-cell, diffuse - diagnostic imaging (2) 2
lymphoma, large b-cell, diffuse - drug therapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
by Maurer, Matthew J and Bachy, Emmanuel and Ghesquières, Hervé and Ansell, Stephen M and Nowakowski, Grzegorz S and Thompson, Carrie A and Inwards, David J and Allmer, Cristine and Chassagne‐Clément, Catherine and Nicolas‐Virelizier, Emmanuelle and Sebban, Catherine and Lebras, Laure and Sarkozy, Clementine and Macon, William R and Feldman, Andrew L and Syrbu, Sergei I and Traverse‐Glehan, Alexandra and Coiffier, Bertrand and Slager, Susan L and Weiner, George J and Witzig, Thomas E and Habermann, Thomas M and Salles, Gilles and Cerhan, James R and Link, Brian K
American Journal of Hematology, ISSN 0361-8609, 11/2016, Volume 91, Issue 11, pp. 1096 - 1101
Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event‐free... 
B-CELL LYMPHOMA | NATIONAL LYMPHOCARE | INTERNATIONAL PROGNOSTIC INDEX | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | VINCRISTINE | NON-HODGKINS-LYMPHOMA | UNIVERSITY | HEMATOLOGY | CHEMOTHERAPY | Prognosis | Humans | Middle Aged | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Male | Treatment Outcome | Young Adult | Disease-Free Survival | Lymphoma, Follicular - epidemiology | Immunotherapy | Survival Analysis | Aged, 80 and over | Adult | Female | Registries | Aged | Early Diagnosis | Lymphomas | Epidemiology | Conferences and conventions | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Bendamustine and rituximab in elderly patients with low‐tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study
by Gyan, Emmanuel and Sonet, Anne and Brice, Pauline and Anglaret, Bruno and Laribi, Kamel and Fruchart, Christophe and Tilly, Hervé and Araujo, Carla and Soubeyran, Pierre and Gonzalez, Hugo and Morineau, Nadine and Nicolas‐Virelizier, Emmanuelle and Ghesquières, Hervé and Salles, Bruno and Bouabdallah, Réda and Orfeuvre, Hubert and Fahri, Jonathan and Couturier, Olivier and Xerri, Luc and Feugier, Pierre and Lymphoma Study Assoc LYSA and Lymphoma Study Association (LYSA) and the Lymphoma Study Association (LYSA)
British Journal of Haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 76 - 86
Summary The treatment of low‐tumour burden follicular lymphoma (LTBFL) remains a challenge. Rituximab‐based strategies may be improved by adding chemotherapy.... 
follicular lymphoma | rituximab | tolerance | efficacy | bendamustine | 1ST-LINE TREATMENT | MANTLE-CELL | RESPONSE CRITERIA | SAFETY | PLUS RITUXIMAB | RANDOMIZED-TRIAL | OPEN-LABEL | INDOLENT | ADVANCED-STAGE | NON-HODGKIN-LYMPHOMA | HEMATOLOGY | Lymphoma, Follicular - drug therapy | Maintenance Chemotherapy - mortality | Humans | Middle Aged | Lymphoma, Follicular - mortality | Male | Treatment Outcome | Tumor Burden | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Maintenance Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Female | Remission Induction - methods | Aged | Aged patients | Elderly people | Chemotherapy | Rituximab | Sepsis | Lymphomas | Lymphoma | Patients | Elderly | Tumors | Geriatrics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University
by Aussedat, Guillaume and Maucort-Boulch, Delphine and Rey, Philippe and Safar, Violaine and Karlin, Lionel and Elsensohn, Mad-Helenie and Lebras, Laure and Sarkozy, Clementine and Bachy, Emmanuel and Favier, Bertrand and Vantard, Nicolas and Sesques, Pierre and Lazareth, Anne and Ferrant, Emmanuelle and Ghergus, Dana and Salles, Gilles and Nicolas-Virelizier, Emmanuelle and Ghesquieres, Herve
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4215 - 4215
Abstract Introduction: standard treatment for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is high-dose chemotherapy followed by autologous... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO
by Avivi, Irit and Arcaini, Luca and Ferretti, Virginia V and Boumendil, Ariane and Finel, Hervé and Milone, Giuseppe and Zaja, Francesco and Liliana, Devizzi and Musso, Maurizio and Didier, Blaise and Bachy, Emmanuel and Wattad, Mohammed and Nicolas‐Virelizier, Emmanuelle and Gramatzki, Martin and Bourhis, Jean‐Henri and Caillot, Denis and Haenel, Anette and Held, Gerhard and Thieblemont, Catherine and Jindra, Pavel and Pohlreich, David and Guilhot, François and Kroschinsky, Frank and Wahlin, Björn and Scheid, Christof and Ifrah, Norbert and Berthou, Christian and Dreger, Peter and Montoto, Silvia and Conconi, Annarita
British Journal of Haematology, ISSN 0007-1048, 09/2018, Volume 182, Issue 6, pp. 807 - 815
Summary The role of autologous stem cell transplantation (ASCT) in patients with marginal zone lymphoma (MZL) is debatable. This study investigated the outcome... 
mucosa‐associated lymphoid tissue lymphoma | autologous transplant | marginal zone lymphoma | mucosa-associated lymphoid tissue lymphoma | PHASE-II | RELAPSED INDOLENT | INDOLENT B-CELL | MALT LYMPHOMA | CHEMOTHERAPY | BENDAMUSTINE PLUS RITUXIMAB | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | MALIGNANCIES | HEMATOLOGY | CLINICAL ACTIVITY | Medical research | Chemotherapy | Analysis | Stem cells | Medicine, Experimental | Bone marrow | Transplantation | Non-Hodgkin's lymphomas | Cancer | Spleen | Autografts | Transplants & implants | Stem cell transplantation | Rituximab | Transplants | Multivariate analysis | Lymphoma | Patients | Survival | Incidence | Mucosal-associated lymphoid tissue | Medical prognosis | Malt | Lymphomas | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers
by Golfier, Camille and Maucort-Boulch, Delphine and Nicolas-Virelizier, Emmanuelle and Rossi, Cedric and Sesques, Pierre and Vantard, Nicolas and Favier, Bertrand and Bachy, Emmanuel and Broussais-Guillaumot, Florence and Ferrant, Emmanuelle and Ghergus, Dana and Karlin, Lionel and Lazareth, Anne and Safar, Violaine and Sarkozy, Clementine and Assaad, Souad and Lebras, Laure and Rey, Philippe and Bastie, Jean-Noel and Traverse-Glehen, Alexandra and Martin, Laurent and Tordo, Jeremie and Berriolo-Riedinger, Alina and Salles, Gilles and Casasnovas, Rene-Olivier and Ghesquieres, Herve
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1629 - 1629
Abstract Purpose International Prognostic Index (IPS) is the most widely used risk stratification index for advanced stage Hodgkin's lymphoma (HL). The use of... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
by Casasnovas, René-Olivier and Bouabdallah, Krimo and Bouabdallah, Reda and Brice, Pauline and Lazarovici, Julien and Ghesquieres, Hervé and Stamatoullas, Aspasia and Dupuis, Jehan and Gac, Anne-Claire and Gastinne, Thomas and Joly, Bertrand and Nicolas-Virelizier, Emmanuelle and Feugier, Pierre and Morschhauser, Franck and Delarue, Richard and Farhat, Hassan and Quittet, Philippe and Berriolo-Riedinger, Alina and Tempescul, Adrian and Edeline, Véronique and Maisonneuve, Hervé and Fornecker, Luc-Matthieu and Lamy, Thierry and Delmer, Alain and Dartigues, Peggy and Martin, Laurent and André, Marc and Mounier, Nicolas and Traverse-Glehen, Alexandra and Meignan, Michel
The Lancet Oncology, ISSN 1470-2045, 02/2019, Volume 20, Issue 2, pp. 202 - 215
Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP ) improves progression-free survival in... 
TRIAL | ABVD | INTERIM-PET | POSITRON-EMISSION-TOMOGRAPHY | ESCALATED BEACOPP | ONCOLOGY | 8 CYCLES | OPEN-LABEL | STAGE-III | INTERNATIONAL PROGNOSTIC SCORE | EARLY CHEMOTHERAPY INTENSIFICATION | Pets | Care and treatment | Lymphomas | Analysis | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma: A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers
by Ghesquieres, Herv and Dalban, Cecile and Nicolas-Virelizier, Emmanuelle and Jardin, Fabrice and Le Bras, Fabien and Le Gouill, Steven and Casasnovas, Rene-Olivier and Vizoso, Seraphine and Hernandez, Caroline and Metzger, Severine and Perol, David and Cartron, Guillaume
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4612 - 4612
Abstract Introduction: high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) is an effective treatment in relapsed follicular lymphoma... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study
by Houillier, Caroline and Ghesquières, Hervé and Chabrot, Cécile and Soussain, Carole and Ahle, Guido and Choquet, Sylvain and Nicolas-Virelizier, Emmanuelle and Bay, Jacques-Olivier and Vargaftig, Jacques and Gaultier, Claude and Touitou, Valérie and Martin-Duverneuil, Nadine and Cassoux, Nathalie and Le Garff-Tavernier, Magali and Costopoulos, Myrto and Faurie, Pierre and Hoang-Xuan, Khê
Journal of Neuro-Oncology, ISSN 0167-594X, 6/2017, Volume 133, Issue 2, pp. 315 - 320
Primary CNS lymphoma (PCNSL) is chemosensitive to high-dose methotrexate-based chemotherapy. However, responses in the elderly are short-lasting and outcome is... 
Primary CNS lymphoma | Neurology | Chemotherapy | Cytarabine | Consolidation | Medicine & Public Health | Rituximab | Oncology | Methotrexate | Elderly patients | 1ST-LINE TREATMENT | IMMUNOCHEMOTHERAPY | MONOTHERAPY | HIGH-DOSE METHOTREXATE | CLINICAL NEUROLOGY | ONCOLOGY | RADIOTHERAPY | PHASE-2 TRIAL | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Rituximab - therapeutic use | Lymphoma - drug therapy | Karnofsky Performance Status | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Female | Aged | Retrospective Studies | Central Nervous System Neoplasms - drug therapy | Lymphomas | Analysis | Cancer | Procarbazine | Toxicity | Central nervous system | Radiation therapy | Lymphoma | Vincristine | Response rates | Age | Neutropenia | Geriatrics | Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
by Manson, Guillaume and Mear, Jean-Baptiste and Herbaux, Charles and Schiano, Jean-Marc and Casasnovas, Olivier and Stamatoullas, Aspasia and Deau, Bénédicte and Schmitt, Anna and Garnier, Georges and Regny, Caroline and Bouabdallah, Krimo and Moles-Moreau, Marie-Pierre and Ghesquieres, Hervé and Tempescul, Adrian and Dulery, Remy and Nicolas-Virelizier, Emmanuelle and Delmer, Alain and Borel, Cecile and Chauchet, Adrien and Damotte, Diane and Dercle, Laurent and Brice, Pauline and Houot, Roch and LYSA
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 115, pp. 47 - 56
Long-term efficacy of anti-PD1 therapy and the need for a consolidation with allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in... 
Checkpoint inhibitors | Anti-PD1 | Allogenic haematopoietic stem cell transplantation | Immunotherapy | Nivolumab | Hodgkin lymphoma | PEMBROLIZUMAB | RESPONSE CRITERIA | ONCOLOGY | SAFETY | PD-1 BLOCKADE | Antimitotic agents | Care and treatment | Stem cells | Transplantation | Lymphomas | Antineoplastic agents | Cancer | Therapy | Refractory materials | Consolidation | Stem cell transplantation | Lymphoma | Survival | Hodgkin's disease | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
by Houot, Roch and Cartron, Guillaume and Bijou, Fontanet and de Guibert, Sophie and Salles, Gilles A and Fruchart, Christophe and Bouabdallah, Krimo and Maerevoet, Marie and Feugier, Pierre and Le Gouill, Steven and Tilly, Hervé and Casasnovas, Rene-Olivier and Moluçon-Chabrot, Cécile and Van Den Neste, Eric and Zachee, Pierre and Andre, Marc and Bonnet, Christophe and Haioun, Corinne and Van Hoof, Achiel and Van Eygen, Koen and Molina, Lysiane and Nicolas-Virelizier, Emmanuelle and Ruminy, Philippe and Morschhauser, Franck
Leukemia, ISSN 0887-6924, 03/2019, Volume 33, Issue 3, pp. 776 - 780
TRIAL | MANTLE-CELL LYMPHOMA | MULTICENTER | MCL-002 | EFFICACY | ONCOLOGY | SPRINT | SAFETY | RITUXIMAB | INVESTIGATORS CHOICE | COMBINATION | HEMATOLOGY | Antineoplastic Agents, Immunological - administration & dosage | Recurrence | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Lenalidomide - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Lymphoma - drug therapy | Animals | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Female | Aged | Lymphocytic leukemia | Care and treatment | Refractory materials | Lymphoma | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma
by Manson, Guillaume and Brice, Pauline and Herbaux, Charles and Silva, Maria and Bouabdallah, Krimo and Deau-Fisher, Bénédicte and Bouteloup, Juliette and Schiano de Collela, Jean Marc and Nicolas-Virelizier, Emmanuelle and Maerevoet, Marie and Ghesquieres, Herve and Stamatoulas Bastard, Aspasia and Antier, Chloe and Poizeau, Florence and Dercle, Laurent and Houot, Roch
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1549 - 1549
Introduction Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, the optimal... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy
by Maurer, Matthew J and Maurer, Matthew J and Ghesquières, Hervé and Ghesquières, Hervé and Jais, Jean-Philippe and Jais, Jean-Philippe and Witzig, Thomas E and Witzig, Thomas E and Haioun, Corinne and Haioun, Corinne and Thompson, Carrie A and Thompson, Carrie A and Delarue, Richard and Delarue, Richard and Micallef, Ivana N and Micallef, Ivana N and Peyrade, Frédéric and Peyrade, Fréd́eric and Macon, William R and Macon, William R and Molina, Thierry Jo and Jo Molina, Thierry and Ketterer, Nicolas and Ketterer, Nicolas and Syrbu, Sergei I and Syrbu, Sergei I and Fitoussi, Olivier and Fitoussi, Olivier and Kurtin, Paul J and Kurtin, Paul J and Allmer, Cristine and Allmer, Cristine and Nicolas-Virelizier, Emmanuelle and Nicolas-Virelizier, Emmanuelle and Slager, Susan L and Slager, Susan L and Habermann, Thomas M and Habermann, Thomas M and Link, Brian K and Link, Brian K and Salles, Gilles and Salles, Gilles and Tilly, Hervé and Tilly, Hervé and Cerhan, James R and Cerhan, James R
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1066 - 1073
Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death... 
RANDOMIZED PHASE-3 TRIAL | ACVBP | ONCOLOGY | PROGNOSIS | ERA | OLDER | RISK | CHOP CHEMOTHERAPY | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Recurrence | Lymphoma, Large B-Cell, Diffuse - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Kaplan-Meier Estimate | Rituximab | Male | Clinical Trials as Topic | Case-Control Studies | Lymphoma, Large B-Cell, Diffuse - mortality | Young Adult | Disease-Free Survival | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged, 80 and over | Adult | Female | Aged | Bios4 | Bios3 | ORIGINAL REPORTS | Hema10
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
by Pott, Christiane and Sehn, Laurie H and Belada, David and Gribben, John and Hoster, Eva and Kahl, Brad and Kehden, Britta and Nicolas-Virelizier, Emmanuelle and Spielewoy, Nathalie and Fingerle-Rowson, Guenter and Harbron, Chris and Mundt, Kirsten and Wassner-Fritsch, Elisabeth and Cheson, Bruce D
Leukemia, ISSN 0887-6924, 08/2019
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
by Cornillon, Jérôme and Daguenet, Elisabeth and Bay, Jacques-Olivier and Chauchet, Adrien and Salles, Gilles and Contentin, Nathalie and Nicolas-Virelizier, Emmanuelle and Mercier, Mélanie and Vallet, Nicolas and Alexis, Magda and Chrétien, Marie-Lorraine and Cluzeau, Thomas and Huynh, Anne and Himberlin, Chantal and Dorvaux, Véronique and Amorim, Sandy and Lejeune, Caroline and de Latour, Régis Peffault and Gyan, Emmanuel
Annals of Hematology, ISSN 0939-5555, 8/2019, Volume 98, Issue 8, pp. 1973 - 1980
High-dose chemotherapy before autologous transplantation is a therapeutic option as consolidation in primary or relapsed lymphoma. Even if BEAM conditioning is... 
Conditioning regimen | BEAM | Medicine & Public Health | Hematology | Autologous transplantation | Oncology | Lymphoma | BAM | INDUCTION FAILURE | MORTALITY | HODGKINS-LYMPHOMA | HIGH-DOSE THERAPY | BEAM CHEMOTHERAPY | HEMATOLOGY | REGIMENS | Autografts | Medical research | Chemotherapy | Analysis | Medicine, Experimental | Bone marrow | Lymphomas | Transplantation | Health aspects | Cancer | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
by Thompson, Carrie A and Ghesquieres, Herve and Maurer, Matthew J and Cerhan, James R and Biron, Pierre and Ansell, Stephen M and Chassagne-Clément, Catherine and Inwards, David J and Gargi, Thérèse and Johnston, Patrick B and Nicolas-Virelizier, Emmanuelle and Macon, William R and Peix, Marie and Micallef, Ivana N and Sebban, Catherine and Nowakowski, Grzegorz S and Porrata, Luis F and Weiner, George J and Witzig, Thomas E and Habermann, Thomas M and Link, Brian K
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3506 - 3512
Purpose We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma... 
CT SCANS | RELAPSE | ONCOLOGY | RITUXIMAB | FOLLOW-UP | AGGRESSIVE NON-HODGKIN | COMPUTED-TOMOGRAPHY | TRANSPLANTATION | France - epidemiology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prospective Studies | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Male | Survival Rate | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Lymphatic Metastasis | Remission Induction | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - epidemiology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Hsr2 | Timg2 | Psc12 | Timg3 | ORIGINAL REPORTS | Hema10
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Impact of the Use of Polymerase Chain Reaction for the Diagnosis and Management of Pneumocystis Jirovecii Pneumoniae in a Retrospective Cohort of Patients with Lymphoid Malignancies
by De Charry, Felicite and Dupont, Damien and Rabodonirina, Meja and Ferlay, Celine and Fuhrmann, Christine and Nicolas-Virelizier, Emmanuelle and Rey, Philippe and Sebban, Catherine and Belhabri, Amine and Biron, Pierre and Blay, Jean-Yves and Ghesquieres, Herve
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 688 - 688
Abstract Introduction: Pneumocystis jirovecii (Pj) is an opportunistic fungus and a common cause of pneumonia (PCP) in immunocompromised patient. The gold... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
by Dupuis, Jehan, MD and Morschhauser, Franck, Prof and Ghesquières, Hervé, MD and Tilly, Hervé, Prof and Casasnovas, Olivier, Prof and Thieblemont, Catherine, Prof and Ribrag, Vincent, MD and Bossard, Céline, MD and Bras, Fabien Le, MD and Bachy, Emmanuel, MD and Hivert, Bénédicte, MD and Nicolas-Virelizier, Emmanuelle, MD and Jardin, Fabrice, Prof and Bastie, Jean-Noel, MD and Amorim, Sandy, MD and Lazarovici, Julien, MD and Martin, Antoine, Prof and Coiffier, Bertrand, Prof
Lancet Haematology, The, ISSN 2352-3026, 2015, Volume 2, Issue 4, pp. e160 - e165
Summary Background Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and... 
Hematology, Oncology and Palliative Medicine | MANAGEMENT | THERAPY | MODEL | HEMATOLOGY | GUIDELINES | Doxorubicin - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Drug Administration Schedule | Humans |